Thyroid dysfunction and fibrin network structure: A mechanism for increased thrombotic risk in hyperthyroid individuals

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1463-1473

  Hooper, J M W ^a   Stuijver, D J F ^b,c   Orme, S M ^d   Van Zaane, B ^b,c   Hess, K ^e   Gerdes, V E ^b,c   Phoenix, F ^a   Rice, P ^a   Smith, K A ^a   Alzahrani, S H ^a   Standeven, K F ^a   Ajjan, R A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; CARBIMAZOLE; COMPLEMENT COMPONENT C3; D DIMER; FIBRIN; FIBRINOGEN; LEVOTHYROXINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAMAZOLE; THYROID HORMONE;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG MEGADOSE; ELECTRON MICROSCOPY; EUTHYROIDISM; EX VIVO STUDY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTHYROIDISM; INTERVENTION STUDY; LOW DRUG DOSE; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; THROMBOSIS; THYROID DISEASE; THYROID FUNCTION; TURBIDIMETRY;

ADULT; BLOOD COAGULATION; CROSS-SECTIONAL STUDIES; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; HYPERTHYROIDISM; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK; THROMBOSIS; THYROID FUNCTION TESTS; THYROID GLAND;

EID: 84860774031     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2894     Document Type: Article

References (42)

1. Bar-Sela S, Ehrenfeld M, Eliakim M 1981 Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 141:1191-1192
2. Danescu LG, Badshah A, Danescu SC, Janjua M, Marandici AM, Matta F, Yaekoub AY, Malloy DJ, Stein PD 2009 Venous thromboembolism in patients hospitalized with thyroid dysfunction. Clin Appl Thromb Hemost 15:676-680
3. Presti CF, Hart RG 1989 Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 117:976-977
4. Squizzato A, Romualdi E, Büller HR, Gerdes VE 2007 Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 92:2415-2420
5. Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer PH, Pijl H, Cohen AF 2001 Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 11:153-160
6. Franchin IM, Montagnan AM, Manzat OF, Vescovi PP 2009 Thyroid dysfunctionand hemostasis: an issue still unresolved. Semin Thromb Hemost 35:288-294
7. Franchin IM, Lipp IG, Targher G 2011 Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review. Clin Appl Thromb Hemost 17:387-392
8. Vescovi PP, Favaloro EJ, Lippi G, Garofano M, Montagnana M, Manzato F, Franchini M 2011 The spectrum of coagulation abnormalities in thyroid disorders. Semin Thromb Hemost 37:7-10
9. Erem C 2006 Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf) 64:323-329
10. Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A 1996 Proneness to formation of tight and rigid fibrin gel structures inmen with myocardial infarction at a young age. Thromb Haemost 76:535-540
11. Undas A, Podolec P, Zawilska K, Pieculewicz M, Jedliñski I, Stepieñ E, Konarska-Kuszewska E, Weglarz P, Duszyñska M, Hanschke E, Przewlocki T, Tracz W 2009 Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 40:1499-1501
12. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW 2000 Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 20:1354-1361
13. Libby P, Ridker PM 2004 Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116(Suppl 6 A):9S-16S
14. Ajja NR, Grant PJ, Futers TS, Brown JM, Cymbalista CM, Boothby M, Carter AM 2005 Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 94:1048-1053
15. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M 2010 Molecular intercommunication between the complement and coagulation systems. J Immunol 185:5628-5636
16. Tedesc OF, Fischett IF, Paus AM, Dobrin AA, Sim RB, Daha MR 1999 Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 36:261-268
17. Shats-Tseytlina EA, Nair CH, Dhall DP 1994 Complement activation: a new participant inthe modulation of fibrin gel characteristics and the progression of atherosclerosis? Blood Coagul Fibrinolysis 5:529-535
18. Distelmaier K, Adlbrecht C, Jakowitsch J, Winkler S, Dunkler D, Gerner C, Wagner O, Lang IM, Kubicek M 2009 Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 102:564-572
19. Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter A, Howell G, Strachan M, Price J, Smith KA, Grant PG, Ajjan RA 2011 A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 10.1007/s00125-011-2301-7
20. Van Zaane B, Squizzato A, Debeij J, Dekkers OM, Meijers JC, Van Zanten AP, Büller HR, Gerdes VE, Cannegieter SC, Brandjes DP 2011 Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. J Thromb Haemost 9:1816-1824
21. Carter AM, Cymbalista CM, Spector TD, Grant PJ 2007 Heritability of clot formation, morphology, and lysis: the Euro CLOT study. Arterioscler Thromb Vasc Biol 27:2783-2789
22. Undas A, Kolarz M, Kopeæ G, Tracz W 2008 Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant 23:2010-2015
23. Mills JD, Ariens RA, Mansfield MW, Grant PJ 2002 Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106:1938-1942
24. Collet JP, Allal IY, Lest YC, Tanguy ML, Silvai NJ, Ankr IA, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G 2006 Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26:2567-2573
25. Undas A, Szułdrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K 2008 Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 196:551-557
26. Ajjan R, Lim BC, Standeven KF, Harrand R, Dolling S, Phoenix F, Greaves R, Abou-Saleh RH, Connell S, Smith DA, Weisel JW, Grant PJ, Ariens RA 2008 Common variation in the C-terminal region of the fibrinogen β-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 111:643-650
27. Skellern GG, Knight BI, Low CK, Alexander WD, McLarty DG, Kalk WJ 1980 The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. Br J Clin Pharmacol 9:137-143
28. Hofbauer LC, Heufelder AE 1997 Coagulation disorders in thyroid diseases. Eur J Endocrinol 136:1-7
29. Dorr M, Robinson DM, Wallaschofski H, Schwahn C, John U, Felix SB, Volzke H 2006 Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab 91:530-534
30. Erem C, Ersoz HO, Karti SS, Ukinc K, Hacihasanoglu A, Deoer O, Telatar M 2002 Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 25:345-350
31. Weetman AP 2003 Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 148:1-9
32. Yu H, Yang Y, Zhang M, Lu H, Zhang J, Wang H, Cianflone K 2006 Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects. Nutr Metab (Lond) 3:13
33. Jafarzadeh A, Poorgholami M, Izadi N, Nemati M, Rezayati M 2010 Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism. Clin Invest Med 33:E271-E279
34. Sørensen CM, Hansen TK, Steffensen R, Jensenius JC, Thiel S 2006 Hormonal regulation of mannan-binding lectin synthesis in hepatocytes. Clin Exp Immunol 145:173-182
35. Zhan GB, Jiang Y, Yang Y, Peng F, Hu X 2008 Correlation between serum thyroxine and complements in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol Lett 29:256-260
36. Potlukova E, Jiskra J, Freiberger T, Limanova Z, Zivorova D, Malickova K, Springer D, Grodecka L, Antosova M, Telicka Z, Pesickova SS, Trendelenburg M 2010 The production of mannanbinding lectin is dependent upon thyroid hormones regardless of the genotype: a cohort study of 95 patients with autoimmune thyroid disorders. Clin Immunol 136:123-129
37. Marongi UF, Cont IM, Murtas ML, Mamel IG, Sorano GG, Martino E 1991 Activation of blood coagulation and fibrinolysis in Graves' disease. Horm Metab Res 23:609-611
38. Marongi UF, Cont IM, Mamel IG, Murtas ML, Balzan OS, Soran OG, Mamusa AM, Martino E 1988 Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest 11:723-725
39. Rogers 2nd JS, Shane SR, Jencks FS 1982 Factor VIII activity and thyroid function. Ann Intern Med 97:713-716
40. Coba NE, Aydemir M 2008 Levels of plasma fibrinogen and D-dimer in subjects with subclinical hyperthyroidism. Med Sci Monit 14:CR42-CR46
41. Michnovicz JJ, Galbraith RA 1990 Effects of exogenous thyroxine on C-2 and C-16α hydroxylations of estradiol in humans. Steroids 55:22-26
42. Humar M, Dohrmann H, Stein P, Andriopoulos N, Goebel U, Roesslein M, Schmidt R, Schwer CI, Loop T, Geiger KK, Pahl HL, Pannen BH 2008 Thionamides inhibit the transcription factor nuclear factor-κB by suppression of Rac1 and inhibitor of κB kinase α. J Pharmacol Exp Ther 324:1037-1044